Fibromyalgia During the COVID-19 Pandemic

Status Active, not recruiting

Clinical Trial Summary

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China, which was reported to the WHO on 31 December 2019.

There is evidence of a high prevalence of psychiatric comorbidities in Fibromyalgia (FM )(especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile.

In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome.

Clinical Trial Description

The first confirmed case relating to the COVID-19 pandemic in the United Arab Emirates was announced on 29 January 2020.

On March 11, the World Health Organization (WHO) declared the global outbreak a pandemic. Many measures have been taken by the UAE government since the COVID-19 outbreak started hitting the region. From Mid March, the UAE had advised all citizens to restrict themselves to essential travel only and had implemented a curfew between 8 pm and 6 am every day starting from the end of March. On April 5th, UAE imposed a two-week lockdown to contain the COVID-19 pandemic and announced there will be disinfection drives.

Many awareness campaigns were initiated by rheumatologists through different media channels advising patients with rheumatic diseases to avoid clinics and hospitals unless they have an emergency. Some healthcare facilities started telemedicine services including rheumatology outpatient clinics. However, most of the clinics and hospitals have maintained open rheumatology clinics aiming to manage emergency cases.

Fibromyalgia (FM) is a chronic disorder characterized by widespread and chronic musculoskeletal pain and other frequent syndromes such as chronic fatigue sleep disturbance, cognitive impairment, irritable bowel disease, depression, and anxiety.

There is evidence of a high prevalence of psychiatric comorbidities in FM (especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile.

In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04422522
Study type	Observational
Source	Al-Azhar University
Contact
Status	Active, not recruiting
Phase
Start date	March 15, 2020
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03149198` - Mat Pilates Method in the Treatment of Women With Fibromyalgia	N/A
Completed	`NCT00965081` - A Study for Adult Patients With Fibromyalgia	Phase 4
Enrolling by invitation	`NCT06100926` - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain	N/A
Recruiting	`NCT05068791` - Psilocybin-facilitated Treatment for Chronic Pain	Early Phase 1
Recruiting	`NCT05801497` - Balneotherapy in Primary Fibromyalgia
Completed	`NCT05361577` - Exopulse Mollii Suit and Fibromyalgia	N/A
Recruiting	`NCT05754190` - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting	`NCT05941780` - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Not yet recruiting	`NCT06424743` - Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training	N/A
Completed	`NCT04771260` - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting	`NCT04690400` - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic	N/A
Recruiting	`NCT05644054` - The Impact of THC on Pain Modulation in Fibromyalgia	N/A
Enrolling by invitation	`NCT04098757` - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed	`NCT01697254` - The CARRA Registry	N/A
Completed	`NCT00678691` - An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue	Phase 4
Recruiting	`NCT04832100` - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting	`NCT05688787` - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia	N/A
Completed	`NCT03905486` - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.